<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601415</url>
  </required_header>
  <id_info>
    <org_study_id>285417</org_study_id>
    <nct_id>NCT04601415</nct_id>
  </id_info>
  <brief_title>Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis</brief_title>
  <acronym>DUO-EF-19</acronym>
  <official_title>Diagnosis of Heart Failure in the Post-COVID-19 Clinic, Primary Care and Hospital Setting Using a Digital Stethoscope With Artificial Intelligence (AI) Electrocardiogram (ECG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abbreviations/acronyms:&#xD;
&#xD;
      DUO-EF = prediction of ejection fraction (EF) using the Eko-DUO digital stethoscope algorithm&#xD;
      HF = heart failure HFrEF = heart failure with reduced ejection fraction COVID-19 =&#xD;
      coronavirus disease 2019 Eko DUO = digital stethoscope device cMRI = cardiac magnetic&#xD;
      resonance imaging ECG = electrocardiogram&#xD;
&#xD;
      Prospective observational study of left ventricular ejection fraction predicted by&#xD;
      application of artificial intelligence to single-lead ECG acquired by a digital stethoscope;&#xD;
      in the post-covid-19 follow up clinic, in patients presenting with heart failure symptoms in&#xD;
      primary care, and in patients attending for echocardiography and cardiac MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abbreviations/acronyms:&#xD;
&#xD;
      DUO-EF = prediction of ejection fraction (EF) using the Eko-DUO digital stethoscope algorithm&#xD;
      HF = heart failure HFrEF = heart failure with reduced ejection fraction COVID-19 =&#xD;
      coronavirus disease 2019 Eko DUO = digital stethoscope device cMRI = cardiac magnetic&#xD;
      resonance imaging ECG = electrocardiogram&#xD;
&#xD;
      AIMS&#xD;
&#xD;
      To demonstrate DUO-EF can identify heart failure (HF) with reduced ejection fraction (HFrEF)&#xD;
      post-COVID-19 where diagnosis would otherwise be missed/delayed To demonstrate DUO-EF can&#xD;
      reliably and accurately diagnose new HFrEF in the primary care setting To further validate&#xD;
      DUO-EF diagnostic performance at-scale against gold-standard investigations (echocardiography&#xD;
      and cardia MRI) To measure if DUO-EF suggestive of HFrEF but with normal gold standard&#xD;
      investigations predicts future risk of developing HFrEF&#xD;
&#xD;
      Methods To demonstrate DUO-EF can identify heart failure (HF) with reduced ejection fraction&#xD;
      (HFrEF) post-COVID-19 where diagnosis would otherwise be missed/delayed To demonstrate DUO-EF&#xD;
      can reliably and accurately diagnose new HFrEF in the primary care setting To further&#xD;
      validate DUO-EF diagnostic performance at-scale against gold-standard investigations&#xD;
      (echocardiography and cardiac magnetic resonance imaging - cMRI) To measure if DUO-EF&#xD;
      suggestive of HFrEF but with normal gold standard investigations predicts future risk of&#xD;
      developing HFrEF&#xD;
&#xD;
      DUO-EF prediction of ejection fraction in patients attending COVID-19 follow up clinic and&#xD;
      comparison with:&#xD;
&#xD;
      subsequent DUO-EF at time of gold-standard investigation for HF ejection fraction as&#xD;
      calculated by gold-standard investigation&#xD;
&#xD;
      DUO-EF prediction of ejection fraction in patients where their GP suspects new heart failure&#xD;
      and comparison with:&#xD;
&#xD;
      subsequent DUO-EF at time of gold-standard investigation ejection fraction as calculated by&#xD;
      gold-standard investigation DUO-EF prediction of ejection fraction in unselected patients&#xD;
      attending for echocardiography or cardiac MRI, comparing DUO-EF predicted with gold-standard&#xD;
      calculated ejection fraction Telephone call follow-up at 24 months for all patients with&#xD;
      DUO-EF suggestive of HFrEF but normal gold standard investigations&#xD;
&#xD;
      OUTCOME MEASURES Area under curve (AUC) of DUO-EF calibrated for detection of EF below 40%;&#xD;
      classification accuracy Positive predictive value of DUO-EF in COVID-19 clinic and GP context&#xD;
      based on subsequent gold-standard estimation of EF; negative predictive value of DUO-EF in&#xD;
      COVID-19 follow up cohort; positive predictive value of DUO-EF at 24 months in those with&#xD;
      negative gold standard investigations Qualitative measurement of patient and clinical end&#xD;
      user acceptability of Eko DUO&#xD;
&#xD;
      POPULATION Group 1: Patients seen in the COVID-19 follow-up clinic (n = 400) Group 2:&#xD;
      Patients seen in primary care with symptoms newly suggestive of heart failure (n = 400) Group&#xD;
      3: All-comers to echocardiography departments across Imperial College Healthcare NHS Trust (n&#xD;
      = 1,500) Group 4: patients undergoing cardiac MRI investigation (n = 100)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under receiver operating curve</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Area under curve (AUC) where maximum value is '1', describing ability of algorithm to discriminate low from not-low ejection fraction</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>GP Referrals</arm_group_label>
    <description>Patients with HF referred by GP to echo department</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Echo patients</arm_group_label>
    <description>Non-selected patients attending echo department in hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG from handheld device</intervention_name>
    <description>Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment</description>
    <arm_group_label>Echo patients</arm_group_label>
    <arm_group_label>GP Referrals</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care population and patients referred to echocardiography department from&#xD;
        in/outpatient settings&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Attendance at GP with ?HF symptoms&#xD;
&#xD;
          -  Referral from GP or elsewhere for echocardiogram in hospital&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, Kapa S, Friedman PA. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019 Sep 7;394(10201):861-867. doi: 10.1016/S0140-6736(19)31721-0. Epub 2019 Aug 1.</citation>
    <PMID>31378392</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Identifiable data will be held within the clinical investigator team</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

